Parkman Healthcare Partners LLC Trims Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Parkman Healthcare Partners LLC cut its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 55.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,588 shares of the medical device company's stock after selling 86,267 shares during the quarter. Parkman Healthcare Partners LLC's holdings in DexCom were worth $4,732,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Blue Whale Capital LLP grew its holdings in DexCom by 91.9% during the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company's stock worth $15,821,000 after acquiring an additional 113,000 shares during the period. Taylor Frigon Capital Management LLC grew its position in shares of DexCom by 51.6% during the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company's stock worth $2,182,000 after buying an additional 11,075 shares during the period. Brooktree Capital Management acquired a new stake in shares of DexCom during the 3rd quarter worth approximately $683,000. National Pension Service grew its holdings in DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company's stock worth $63,671,000 after purchasing an additional 37,363 shares during the period. Finally, Intact Investment Management Inc. acquired a new stake in DexCom in the third quarter worth $650,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Price Performance

Shares of DXCM stock traded up $0.10 on Wednesday, reaching $81.01. The company's stock had a trading volume of 3,218,346 shares, compared to its average volume of 3,914,188. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a market capitalization of $31.64 billion, a P/E ratio of 48.51, a PEG ratio of 2.43 and a beta of 1.12. The stock's 50 day simple moving average is $71.83 and its 200-day simple moving average is $86.83.

Insider Activity

In related news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,431 shares of company stock worth $399,319. 0.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently commented on the company. Sanford C. Bernstein boosted their target price on DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a research report on Friday, October 25th. Leerink Partners dropped their price objective on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. StockNews.com lowered shares of DexCom from a "buy" rating to a "hold" rating in a research note on Saturday, November 2nd. Oppenheimer dropped their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Finally, Royal Bank of Canada dropped their price target on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, DexCom presently has a consensus rating of "Moderate Buy" and an average price target of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.